Jeffrey Silberzweig is a Nephrology physician affiliated with Cornell University. OpenAlex indexes 63 publications with 895 citations (h-index 12); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
505 E 70th St
2nd Floor
New York, NY 100214872
Telephone
212-746-1562Provider last certified this registry record 9 May 2024.
Clinical trials
- Procalcitonin and Brain Natriuretic Peptides in Patients With Chronic Kidney Disease.
Sponsor: The Rogosin Institute
- Post Approval Study of Lixelle for the Treament of Dialysis-Related Amyloidosis
Sponsor: Kaneka Medical America LLC
- Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
Sponsor: Kaneka Medical America LLC
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Vifor Pharma, Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
37.9%Statin19%Atorvastatin Calcium100%Part D<11 patientsCentral alpha-2 Adrenergic Agonist19%Guanfacine Hcl100%Part D<11 patientsGenitourinary & hormones
22.4%Cholinergic Muscarinic Antagonist22.4%Oxybutynin Chloride Er100%Part D<11 patientsMetabolism & gastrointestinal
20.7%H2 blocker20.7%Famotidine100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Role of National and International Renal Organizations in Providing Kidney Care in Disasters
Advances in Kidney Disease and Health
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Richard Devereux, MD
Cornell University
Thomas Walsh, MD
Cornell University
Cora Sternberg, MD
Cornell University
George Alexopoulos, MD
Cornell University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”